CYPH
Cypherpunk Technologies Inc.
There isn't enough reported data to score CYPH yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CYPH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CYPH's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CYPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 3.5x | $1.95 | — |
| Cheap | 3.7x | $2.09 | +7.4% |
| Fair | 5.4x | $3.00 | +54% |
| Forward | 5.6x | $1.95 | — |
| Expensive | 13x | $7.33 | +276% |
Historical ranges are pointers, not guarantees.
CYPH's PE is 3.5x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CYPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CYPH to return to profit, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CYPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | -37% |
| Q2 2026 | $0.56 | +$2.11 |
| Q1 2026 | -$0.02 | +$1.65 |
| Q4 2025 | $0.07 | +$1.88 |
| Q3 2023 | -$5.72 | -$1.12 |
| Q2 2023 | -$6.51 | -$1.81 |
| Q1 2023 | -$7.10 | -$2.70 |
| Q4 2022 | -$4.80 | -$0.10 |
CYPH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CYPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2021 | $375K | 0% |
| Q3 2021 | $375K | 0% |
| Q2 2021 | $375K | 0% |
| Q1 2021 | $375K | 0% |
HIMS has the stronger quarterly revenue trend. Revenue is flat for CYPH versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | -2797% | -889 points |
| Q3 2021 | -3237% | -1235 points |
| Q2 2021 | -2567% | -568 points |
| Q1 2021 | -2446% | -744 points |
| Q4 2020 | -1908% | N/A |
| Q3 2020 | -2002% | N/A |
| Q2 2020 | -1999% | N/A |
| Q1 2020 | -1702% | N/A |
CYPH's operating margin was −2797% last quarter, down 889 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CYPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | +$11.8M |
| Q1 2026 | -$3.4M | +$11.1M |
| Q4 2025 | -$6.6M | +$8.9M |
| Q3 2025 | -$8.3M | +$7.3M |
| Q2 2025 | -$14.5M | -$815K |
| Q1 2025 | -$14.5M | +$1M |
| Q4 2024 | -$15.5M | -$5.1M |
| Q3 2024 | -$15.6M | -$5.1M |
CYPH has burned cash in almost every quarter: −$21M over the past year, against −$60M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CYPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +49.2M shares |
| 1 year | +427% | +176M shares |
| 3 years | +1819% | +206M shares |
| 5 years | +2748% | +210M shares |
CYPH has 217M diluted shares, up 427% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CYPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CYPH Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CYPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.7 | Neutral |
| Stochastic | 55.7 | Neutral |
CYPH's weekly RSI is 50 (neutral) and its Stochastic is 56 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CYPH PE vs Healthcare Sector
| Metric | CYPH | Sector median | Relative |
|---|---|---|---|
| PE | 3.5x | 26x | 87% below |
| PE % | 14 | 29 | 15 pts below |
CYPH is trading at 3.5x earnings, a 87% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CYPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.91 | 33% below |
| 20 week MA | $1.97 | 1% below |
| 50 week MA | $1.32 | 48% above |
| 100 week MA | $1.06 | 84% above |
| 200 week MA | $2.12 | 8% below |
CYPH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CYPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.0 | $22.2 | +102% |
| 2021 | $22.2 | $29.5 | +33% |
| 2022 | $29.5 | $4.70 | -84% |
| 2023 | $4.70 | $4.14 | -12% |
| 2024 | $4.14 | $2.95 | -29% |
| 2025 | $2.95 | $1.20 | -59% |
| 2026 YTD | $1.20 | $1.95 | +63% |
CYPH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.